Found 12 articles for: "Basal Cell Carcinoma"
The Emerging Role of Metformin in Skin Cancer: Mechanistic and Clinical Insights
May 2026 | Volume 25 | Issue 5 | Original Article | 444 | Copyright © May 2026
Background: Metformin, widely used for type 2 diabetes mellitus, has demonstrated antitumor effects through modulation of metabolic and immune pathways. This review explores its ...
Read MoreCurrent Use of Neoadjuvant Hedgehog Inhibitors Among Mohs Surgeons: Results of a Cross-Sectional Survey
July 2025 | Volume 24 | Issue 7 | Features | 722 | Copyright © July 2025
Recent studies have demonstrated functional and cosmetic benefits with the use of hedgehog pathway inhibitors in the neoadjuvant setting for basal cell carcinoma (BCC). This study investigated th...
Read MoreEfficacy and Safety of Hedgehog Inhibitors for Advanced Basal Cell Carcinoma: An Expert Consensus Panel
May 2025 | Volume 24 | Issue 5 | Original Article | 465 | Copyright © May 2025
Background: Hedgehog inhibitors (HHIs) can be used to treat patients with locally advanced basal cell carcinoma (laBCC) who are not candidates for surgery or radiation or whose t...
Read MoreMedical and Surgical Management of Multifocal Superficial Basal Cell Carcinoma
May 2025 | Volume 24 | Issue 5 | Original Article | 483 | Copyright © May 2025
Background: Multifocal superficial basal cell carcinoma (sBCC) is a subtype of BCC characterized by subclinical extension of noncontiguous tumor islands and high recurrence rates...
Read MoreNeoadjuvant Sonidegib for the Management of Locally Advanced Basal Cell Carcinoma: A Case Report
March 2025 | Volume 24 | Issue 3 | Case Reports | 329 | Copyright © March 2025
Neoadjuvant Hedgehog Pathway Inhibitor (HPI) therapy, utilizing sonidegib and vismodegib, has shown great potential in managing locally advanced basal cell carcinoma (laBCC). While effective, the...
Read MoreCryosurgery and 5-Fluorouracil Combination Therapy for Treatment of Bowen's Disease and Superficial Basal Cell Carcinoma
December 2023 | Volume 22 | Issue 12 | Original Article | 1166 | Copyright © December 2023
Background: Non-melanoma skin cancer (NMSC), which includes both Bowen's disease (BD) and superficial basal cell carcinoma (sBCC), is the most commonly diagnosed cancer in Canada...
Read MoreNon-Invasive Treatment of Basal Cell Carcinoma: Photodynamic Therapy Following Curettage
May 2023 | Volume 22 | Issue 5 | Original Article | 481 | Copyright © May 2023
Background: To investigate the effectiveness, safety, patient satisfaction, and cosmetic outcome of Methyl Aminolevulinate-Photodynamic Therapy (MAL-PDT) following curettage in o...
Read MorePigmented Basal Cell Carcinoma: An Argument for Sub-Classification
February 2023 | Volume 22 | Issue 2 | Features | 217 | Copyright © February 2023
Basal cell carcinoma (BCC) has several subclassifications, including pigmented basal cell carcinoma. In our clinical experience, we have found that pigmented basal cell carcinoma itself has multiple s...
Read MoreGiant Basal Cell Carcinoma of the Axilla: 8-year Follow-up of a Case Treated with Excision, Vismodegib, and Radiotherapy
May 2022 | Volume 21 | Issue 5 | Case Reports | 531 | Copyright © May 2022
Axillary giant basal cell carcinoma is extremely rare and remains challenging for physicians. The few reported cases have a relatively short-term follow-up, and none were treated with an oral hedgehog...
Read MoreCharacteristics of Superficial Basal Cell Carcinomas Containing More Aggressive Subtypes on Final Histopathologic Diagnosis
August 2021 | Volume 20 | Issue 8 | Original Article | 874 | Copyright © August 2021
Background: The prognosis and treatment of basal cell carcinoma (BCC) are largely dependent on tumor subtype, which is typically determined by punch or shave biopsy. Data regarding co...
Read MoreBasal Cell Carcinoma Gene Mutations Differ Between Asian, Hispanic, and Caucasian Patients: A Pilot Study
May 2021 | Volume 20 | Issue 5 | Original Article | 504 | Copyright © May 2021
Background: Basal cell carcinoma (BCC) is the most common malignancy worldwide. While most BCCs are treated surgically, adv...
Read MoreCharacteristics of Superficial Basal Cell Carcinomas Containing More Aggressive Subtypes on Final Histopathologic Diagnosis
March 2021 | Volume 20 | Issue 3 | Original Article | 283 | Copyright © March 2021
Background: The prognosis and treatment of basal cell carcinoma (BCC) are largely dependent on tumor subtype, which is typically determined by punch or shave biopsy. Data regarding co...
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
